MMMark Joseph Murphy

Mark Joseph Murphy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mark Joseph Murphy has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy of IDOR‐1117‐2520, a novel, orally available CCR6 antagonist in preclinical models of skin dermatitis

    by Paulina Kulig, Pijus Brazauskas, Madeleine Suffiotti, Emilie Raoult, Ulrike Babilonski, Bérengère Renault, Ursula Grieder, Enrico Vezzali, Peter Blattmann, Marianne M. Martinic, et al.

    Background and Purpose: The chemokine receptor CCR6 guides pathogenic T17 cells, implicated in autoimmune diseases including psoriasis, to sites of inflammation via the chemokine CCL20. Therefor, pharmacological inhibition of CCR6+ immune cell migration provides a novel therapeutic approach. Translatability of such an intervention has not yet been assessed in detail. We evaluated the translatability of the Aldara® mouse model induced skin inflammation to psoriasis, with particular focus on immune cell trafficking and assessed the efficacy of IDOR‐1117‐2520, a highly selective, potent and orally available CCR6 small inhibitor.Experimental Approach: Effects of IDOR‐1117‐2520 were investigated in the Aldara® and IL23 mouse models of skin inflammation using flow cytometry, RNA sequencing and transcriptome‐based cell type deconvolution approaches to characterise immune cell migration patterns. These results were compared to human psoriasis transcriptomics data.Key Results: IDOR‐1117‐2520 dose dependently reduced infiltration of CCR6+ immune cells into inflamed skin, and was equally efficacious as IL‐17 and IL‐23 inhibition in models of skin inflammation. Pathway analysis showed molecular similarities in the immune response between human psoriasis and the Aldara® mouse model. IL‐17/IL‐23 pathway genes were expressed in both human psoriasis and the mouse model. CCR6 inhibition modulated multiple pathways associated with inflammation beyond the proximal IL‐17/IL‐23 pathway. A chemokine–chemokine receptor interaction map implicated CCL20‐CCR6 as the dominant axis in recruiting pathogenic T17 cells in both the model and in human psoriasis.Conclusion and Implications: IDOR‐1117‐2520 could provide a promising novel targeted approach to treating psoriasis and, potentially, other autoimmune diseases involving the CCR6/CCL20 axis and the IL‐17/IL‐23 pathway. IDOR‐1117‐2520 is currently being evaluated in a clinical phase 1 trial (ISRCTN28892128).


  • Pharmacodynamics of the S1P1 receptor modulator cenerimod in a phase 2b randomised clinical trial in patients with moderate to severe SLE

    by Madeleine Suffiotti, Pijus Brazauskas, Marcel Peter Keller, Ouali Berkani, Gustavo Seifer, Peter Cornelisse, Mark Joseph Murphy, Daniel Stefan Strasser

    Background Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterised by autoreactive T and B lymphocytes. Sphingosine-1-phosphate (S1P) is involved in lymphocyte egress from peripheral lymphoid organs into the circulation. In phase 2a clinical trial, the potent, selective S1P1 receptor modulator cenerimod reduced circulating antibody-secreting cells and interferon (IFN)-associated biomarkers. Objectives Pharmacodynamic effects of 2 and 4 mg cenerimod were evaluated in the phase 2b clinical trial (CARE) in moderate to severe patients with SLE (NCT03742037). Methods Blood samples were collected at baseline and after 6 months of treatment with cenerimod or placebo from CARE. The gene expression signatures for type 1 interferon (IFN-1), IFN-gamma and plasma cells were used to assess dose-dependent pharmacodynamic effects of cenerimod. Cell-type deconvolution was performed to estimate cell abundance. Results Cenerimod 4 mg reduced IFN-associated protein and gene signature biomarkers after 6 months compared with placebo. A larger decrease of IFN proteins was evident in IFN-1 high patients compared with IFN-1 low patients. The median IFN-1 score in the IFN-1 high patients was reduced after 6 months of cenerimod 4 mg and the transition from IFN-1 low to high status compared with placebo was prevented. Cenerimod 4 mg exhibited a larger effect size on the pharmacodynamic biomarkers IFN-1, IFN-gamma and plasma cells compared with cenerimod 2 mg. Conclusions This study further characterised the mechanism of action of cenerimod in patients with SLE and substantiated the scientific rationale for cenerimod 4 mg in the phase 3 clinical trials in moderate to severe SLE (OPUS-1/-2).


  • Open Access

    0751 The use of a Digitally Milled Oral Appliance in the Treatment of Severe Obstructive Sleep Apnea

    by Mark Murphy, John Remmers, Erin Mosca

    Oral appliances (OAs) that advance the mandible are commonly used for the treatment of mild to moderate obstructive sleep apnea (OSA) but are less accepted as a therapy for severe OSA, likely due to their supposed lower rate of therapeutic success in that population. However, the preference for OAT over CPAP and relative lack of other non-surgical treatment options highlights the need for acceptance of OAT for all severities of OSA. Data from two prospective studies that collected data on OAT efficacy were analyzed retrospectively to evaluate the success rate of OAT in severe OSA using a digitally milled OA. Data from the severe OSA cohorts of two studies conducted for the validation of an in-home auto-titration test were evaluated. Study participants (n = 41 with severe OSA) received a precision iterative advancement OA (ProSomnus Sleep Technologies, Pleasanton, CA). The OAs used in the studies were CAD/CAM generated from digital intraoral scans and precision milled from control cured grade PMMA. The OAs consisted of sets of upper and lower trays that, when interfaced together, allowed for advancement of the mandible to a treated position. Oral appliances were set to the target protrusion provided by an in-home auto-titration test that predicts response to OAT (MATRx plus; Zephyr Sleep Technologies, Calgary, Alberta, Canada). Participants not predicted to respond to OAT were assigned a sham mandibular protrusion. Oral appliance therapy was initiated at the target protrusive position, sham position, or highest tolerated position for individuals who were unable to have their OA inserted at target. Once participants were habituated to OAT, a 2-night home sleep apnea test (HSAT) was conducted to assess treatment efficaciousness, and the mandible was advanced as necessary to lower the respiratory event index (REI). The study population included 36 male and 5 female participants with a mean age of 50.6 ± 8.4 years (range: 32-74 years), mean BMI of 32.1 ± 5.5 kg/m2 (range: 19.8-45.4 kg/m2), mean baseline REI of 49.5 ± 17.1 h-1 (range: 30.3-101.8 h-1), and median Epworth Sleepiness Scale (ESS) score of 10 (range: 0-23). Oral appliance therapy was well-tolerated in the study population. The majority of study participants achieved some level of therapeutic success, with 73.2% of participants achieving a decrease in REI from baseline of at least 50% and 68.3% achieving an REI < 15 h-1. Of the study participants who achieved an REI < 15 h-1, the average protrusive position of the OA was 86.7±15.3% (range: 54.8-100%). The OAs used in the studies provided efficacious treatment for the majority of individuals with severe OSA, indicating that oral appliance therapy could be a suitable alternative to CPAP. The rate of therapeutic success was higher than that reported previously in the literature and might be a result of the precision of appliances generated from digital intraoral scans using a CAD/CAM approach. Study data were collected by and used with the permission of Zephyr Sleep Technologies. ProSomnus Sleep Technologies provided the OAs used in the studies.

  • Open Access

    In Vitro Characterization of Sphingosine 1-Phosphate Receptor 1 (S1P1) Expression and Mediated Migration of Primary Human T and B Cells in the Context of Cenerimod, a Novel, Selective S1P1 Receptor Modulator

    by Lisa Schlicher, Paulina Kulig, Audrey von Münchow, Mark J. Murphy, Marcel P. Keller

    Cenerimod is a potent, selective sphingosine 1-phosphate receptor 1 (S1P1) modulator currently investigated in a Phase IIb study in patients with systemic lupus erythematosus (SLE) (NCT03742037). S1P1 receptor modulators sequester circulating lymphocytes within lymph nodes, thereby reducing pathogenic autoimmune cells (including T and B lymphocytes) in the bloodstream and inflamed tissues, making them an effective therapeutic concept for autoimmune disorders. Although the effect of S1P receptor modulators in reducing circulating lymphocytes is well documented, the precise molecular role of the S1P1 receptor on these cell types is not fully understood. In this study, the mode of action of cenerimod on human primary lymphocytes in different activation states was investigated focusing on their chemotactic behavior towards S1P in real-time, concomitant to S1P1 receptor expression and internalization dynamics. Here, we show that cenerimod effectively prevents T and B cell migration in a concentration-dependent manner. Interestingly, while T cell activation led to strong S1P1 re-expression and enhanced migration; in B cells, an enhanced migration capacity and S1P1 receptor surface expression was observed in an unstimulated state. Importantly, concomitant treatment with glucocorticoids (GCs), a frequently used treatment for autoimmune disorders, had no impact on the inhibitory activity of cenerimod on lymphocytes.


  • Open Access

    Cenerimod, a selective S1P1 receptor modulator, improves organ-specific disease outcomes in animal models of Sjögren’s syndrome

    by Estelle Gerossier, Saba Nayar, Sylvie Froidevaux, Charlotte G. Smith, Celine Runser, Valentina Iannizzotto, Enrico Vezzali, Gabin Pierlot, Ulrich Mentzel, Mark J. Murphy, et al.

    Background: Sjögren’s syndrome is a systemic autoimmune disease characterized by immune cells predominantly infiltrating the exocrine glands and frequently forming ectopic lymphoid structures. These structures drive a local functional immune response culminating in autoantibody production and tissue damage, associated with severe dryness of mucosal surfaces and salivary gland hypofunction. Cenerimod, a potent, selective and orally active sphingosine-1-phosphate receptor 1 modulator, inhibits the egress of lymphocytes into the circulation. Based on the mechanism of action of cenerimod, its efficacy was evaluated in two mouse models of Sjögren’s syndrome. Methods: Cenerimod was administered in two established models of Sjögren’s syndrome; firstly, in an inducible acute viral sialadenitis model in C57BL/6 mice, and, secondly, in the spontaneous chronic sialadenitis MRL/lpr mouse model. The effects of cenerimod treatment were then evaluated by flow cytometry, immunohistochemistry, histopathology and immunoassays. Comparisons between groups were made using a Mann-Whitney test. Results: In the viral sialadenitis model, cenerimod treatment reduced salivary gland immune infiltrates, leading to the disaggregation of ectopic lymphoid structures, reduced salivary gland inflammation and preserved organ function. In the MRL/lpr mouse model, cenerimod treatment decreased salivary gland inflammation and reduced T cells and proliferating plasma cells within salivary gland ectopic lymphoid structures, resulting in diminished disease-relevant autoantibodies within the salivary glands. Conclusions: Taken together, these results suggest that cenerimod can reduce the overall autoimmune response and improve clinical parameters in the salivary glands in models of Sjögren’s syndrome and consequently may reduce histological and clinical parameters associated with the disease in patients.


  • Open Access

    Preclinical to clinical translation of cenerimod, a novel S1P1 receptor modulator, in systemic lupus erythematosus

    by Daniel S Strasser, Sylvie Froidevaux, Virginie Sippel, Estelle Gerossier, Ursula Grieder, Gabin M Pierlot, Andrea Kieninger-Graefitsch, Enrico Vezzali, Anna K Stalder, Bérengère Renault, et al.

    Objectives: SLE is an autoimmune disease characterised by aberrant lymphocyte activation and autoantibody production. This study provides an in-depth preclinical and clinical characterisation of the treatment effect of cenerimod, a sphingosine-1-phosphate receptor type 1 (S1P1) modulator, in SLE. Methods: Cenerimod effect on lymphocyte numbers, organ pathology, inflammation, and survival was evaluated in the MRL/lpr lupus mouse model. Lymphocytes from healthy subjects and patients with SLE were assessed for cenerimod-induced S1P1 receptor internalisation. Lymphocyte subsets and inflammatory biomarkers were characterised in a 12-week phase 2 clinical study (NCT-02472795), where patients with SLE were treated with multiple doses of cenerimod or placebo. Results: In MRL/lpr mice treated with cenerimod, blood lymphocytes were reduced, leading to reduced immune infiltrates into tissue, and decreased tissue pathology, proteinuria, and inflammation, resulting in increased survival. Cenerimod was potent and efficacious in inducing S1P1 receptor internalisation in lymphocytes in both healthy subjects and patients with SLE. In patients with SLE, 12-week cenerimod treatment resulted in a dose-dependent reduction of blood lymphocytes, antibody-secreting cells (ASC), and plasma IFN-α. Conclusion: Cenerimod significantly ameliorated systemic and organ-specific pathology and inflammation in a mouse model of SLE. In lymphocytes from patients with SLE, the S1P1 receptor remained functional despite concomitant background medication. The preclinical lymphocyte reduction translated to patients with SLE and resulted in the normalisation of ASC and the reduction of IFN-associated biomarkers. The efficacy and safety of cenerimod is being further investigated in a long-term clinical study in patients with SLE (CARE; NCT-03742037).


  • Open Access

    A design methodology for domain-optimized power-efficient supercomputing

    by Marghoob Mohiyuddin, Mark Murphy, Leonid Oliker, John Shalf, John Wawrzynek, Samuel Williams


  • The self-management of skills by persons with mental retardation

    by Ralph P. Ferretti, Al R. Cavalier, Mark J. Murphy, Roberta Murphy